cyc 682 has been researched along with lenalidomide in 1 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 3,532 | 725 | 2,850 |
| Protein | Taxonomy | cyc 682 (IC50) | lenalidomide (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.19 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.5953 | |
| Protein cereblon | Homo sapiens (human) | 1.6572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, MR; Gojo, I | 1 |
1 other study(ies) available for cyc 682 and lenalidomide
| Article | Year |
|---|---|
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |